The Effect of Alendronate in the Treatment of Osteopenia due to Acute Leukemia

The Evaluation of The effects of Alendronates on Osteopenia in Children with Acute Leukemia

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200916048733N1

Enrollment

Registered

2020-10-30

Start date

2020-03-02

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Acute Lymphoblastic Leukemia. Condition 2: Acute Myeloblastic Leukemia. Acute lymphoblastic leukemia [ALL] Acute myeloblastic leukemia

Interventions

Intervention group: 30 patients with acute leukemia for six months alendronate with the chemical composition of alendronate sodium, tablets with a concentration of 70 mg, with a dose of 35 mg once a w

Eligibility

Sex/Gender

All

Age

2 Years to 15 Years

Inclusion criteria

Inclusion criteria: Children under 15 years Children with acute lymphoblastic leukemia Children with acute myeloblastic leukemia

Exclusion criteria

Exclusion criteria: Children with chronic leukemia Children under 2 years

Design outcomes

Primary

Measure	Time frame
Serum level of vitamin D. Timepoint: Measurement of serum vitamin D levels at baseline (before intervention) and six months after Alendronate administration. Method of measurement: Enzyme-linked Immunosorbent assay (ELISA).;Serum level of Calcium. Timepoint: Measurement of serum calcium levels at baseline (before intervention) and six months after Alendronate administration. Method of measurement: Biochemistry auto-analyzer.;Serum level of Phosphorus. Timepoint: Measurement of serum phosphorus levels at baseline (before intervention) and six months after Alendronate administration. Method of measurement: Biochemistry auto-analyzer.;Bone density. Timepoint: Bone density evaluation at baseline (before intervention) and six months after Alendronate administration. Method of measurement: Dual Energy X-ray Absorptiometry (DEXA).;Serum Alkaline Phosphatase levels. Timepoint: Measurement of serum alkaline phosphatase levels at the beginning of the study (before the intervention) and six months after the use of alendronate. Method of measurement: Biochemistry auto-analyzer.	—

Measure

Time frame

Serum level of vitamin D. Timepoint: Measurement of serum vitamin D levels at baseline (before intervention) and six months after Alendronate administration. Method of measurement: Enzyme-linked Immunosorbent assay (ELISA).;Serum level of Calcium. Timepoint: Measurement of serum calcium levels at baseline (before intervention) and six months after Alendronate administration. Method of measurement: Biochemistry auto-analyzer.;Serum level of Phosphorus. Timepoint: Measurement of serum phosphorus levels at baseline (before intervention) and six months after Alendronate administration. Method of measurement: Biochemistry auto-analyzer.;Bone density. Timepoint: Bone density evaluation at baseline (before intervention) and six months after Alendronate administration. Method of measurement: Dual Energy X-ray Absorptiometry (DEXA).;Serum Alkaline Phosphatase levels. Timepoint: Measurement of serum alkaline phosphatase levels at the beginning of the study (before the intervention) and six months after the use of alendronate. Method of measurement: Biochemistry auto-analyzer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLaleh tokhmechian

Tabriz University of Medical Sciences

dr.tokhmechian@yahoo.com+98 41 3526 2265

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026